Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort

M.G Quaranta,S Rosato,L Ferrigno,D.C Amoruso,M Monti,P Di Stefano,R Filomia,F Tamburini,G Migliorino,A Zanetto,E Degasperi,L Cavalletto,G Brancaccio,P Blanc,M Cannizzaro,E Castelli,G Morsica,A Licata,L.A Kondili

doi:10.1016/j.dld.2018.11.151

Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort

M.G Quaranta, S Rosato + Show 17 more

https://doi.org/10.1016/j.dld.2018.11.151

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Feb 1, 2019

Affiliation: Istituto Superiore di Sanità, Center for Global Health, University of Florence, University of Messina, Sapienza University of Rome, Azienda Ospedaliera San Gerardo, Azienda Ospedaliera Universitaria Pisana, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, University of Padua, Ospedale SS. Annunziata, Ospedale Vincenzo Cervello, IRCCS Ospedale San Raffaele, University of Palermo

#Drug-drug Interaction Profile #PITER Cohort + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Introduction: In a previous study, based on PITER cohort data, it was reported that of patients, undergoing direct acting antiviral (DAA) therapy, 30%-44%, are at risk of potential drug-drug interactions (DDI).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Digestive and Liver Disease

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.